The New England journal of medicine
-
Randomized Controlled Trial Multicenter Study
Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy.
Type 2 diabetes mellitus is the leading cause of kidney failure worldwide, but few effective long-term treatments are available. In cardiovascular trials of inhibitors of sodium-glucose cotransporter 2 (SGLT2), exploratory results have suggested that such drugs may improve renal outcomes in patients with type 2 diabetes. ⋯ In patients with type 2 diabetes and kidney disease, the risk of kidney failure and cardiovascular events was lower in the canagliflozin group than in the placebo group at a median follow-up of 2.62 years. (Funded by Janssen Research and Development; CREDENCE ClinicalTrials.gov number, NCT02065791.).
-
Comment Letter
Patient Safety under Flexible and Standard Duty-Hour Rules.